Guy A. Young, MD

Professor of Pediatrics (Clinical Scholar)

Image of Guy A. Young, MD
Is this your profile? Click to edit

Overview

Following medical school, I completed my residency in pediatrics at Schneider Children’s Hospital-Long Island Jewish Medical Center which is part of the Albert Einstein College of Medicine. I then completed a fellowship in pediatric hematology/oncology at Children’s National Medical Center in Washington, DC which is part of the George Washington University School of Medicine. I then began my research career at the Children’s Hospital of Orange County under the mentorship of Dr. Diane Nugent. There, I became interested in improving the treatment for patients with hemophilia and inhibitors and for children with blood clots. I received my first independent grants there inculding a grant from the FDA to study a new anticoagulant in children. In addition, I became interested in thromboelastography. In 2007, I moved the Children’s Hospital Los Angeles where I am continuing to perform research in the same areas as I had started in Orange County.

Awards

  • National Hemophilia Foundation: Physician of the Year, 2013

Research Funding

  • Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    NIH · R01HL095110 · Sep 26, 2008 – Jan 31, 2013 · Role: Principal Investigator
  • FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    NIH · R01FD003091 · Sep 20, 2006 – May 31, 2009 · Role: Principal Investigator

Publications

  • Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life. J Adv Pract Oncol. 2022 May; 13(Suppl 3):7-20.. View in PubMed
  • Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv. 2022 06 14; 6(11):3422-3432.. View in PubMed
  • Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Jul; 28(4):548-556.. View in PubMed
  • Direct oral anticoagulants for use in paediatrics. Lancet Child Adolesc Health. 2022 03; 6(3):207-214.. View in PubMed
  • A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children’s Hospital-Acquired Thrombosis Consortium. Pediatr Crit Care Med. 2022 01 01; 23(1):e1-e9.. View in PubMed
  • Can we do something about ICH in hemophilia? Blood. 2021 12 30; 138(26):2750-2751. Young G . View in PubMed
  • Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022 03; 69(3):e29522.. View in PubMed
  • Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response. Thromb Haemost. 2022 Jun; 122(6):913-925.. View in PubMed
  • Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children. J Pediatr. 2022 01; 240:14-23.. View in PubMed
  • Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: A report from the CHAT Consortium. J Thromb Haemost. 2022 01; 20(1):133-137.. View in PubMed